JP7303802B2 - Ａ３３抗体組成物および放射性免疫療法におけるその使用方法 - Google Patents

Ａ３３抗体組成物および放射性免疫療法におけるその使用方法 Download PDF

Info

Publication number
JP7303802B2
JP7303802B2 JP2020516818A JP2020516818A JP7303802B2 JP 7303802 B2 JP7303802 B2 JP 7303802B2 JP 2020516818 A JP2020516818 A JP 2020516818A JP 2020516818 A JP2020516818 A JP 2020516818A JP 7303802 B2 JP7303802 B2 JP 7303802B2
Authority
JP
Japan
Prior art keywords
antibody
seq
antigen
antibodies
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020516818A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020534017A5 (enExample
JP2020534017A (ja
Inventor
ジーハオ ウー
ホン シュー
ナイ－コン チュン
Original Assignee
メモリアル スローン ケタリング キャンサー センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2020534017A publication Critical patent/JP2020534017A/ja
Publication of JP2020534017A5 publication Critical patent/JP2020534017A5/ja
Priority to JP2023103361A priority Critical patent/JP2023138957A/ja
Application granted granted Critical
Publication of JP7303802B2 publication Critical patent/JP7303802B2/ja
Priority to JP2024215117A priority patent/JP2025061650A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2020516818A 2017-09-23 2018-09-21 Ａ３３抗体組成物および放射性免疫療法におけるその使用方法 Active JP7303802B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023103361A JP2023138957A (ja) 2017-09-23 2023-06-23 Ａ３３抗体組成物および放射性免疫療法におけるその使用方法
JP2024215117A JP2025061650A (ja) 2017-09-23 2024-12-10 Ａ３３抗体組成物および放射性免疫療法におけるその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762562373P 2017-09-23 2017-09-23
US201762562374P 2017-09-23 2017-09-23
US62/562,373 2017-09-23
US62/562,374 2017-09-23
PCT/US2018/052253 WO2019060750A2 (en) 2017-09-23 2018-09-21 A33 ANTIBODY COMPOSITIONS AND METHODS OF USE IN RADIOIMMUNOTHERAPY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023103361A Division JP2023138957A (ja) 2017-09-23 2023-06-23 Ａ３３抗体組成物および放射性免疫療法におけるその使用方法

Publications (3)

Publication Number Publication Date
JP2020534017A JP2020534017A (ja) 2020-11-26
JP2020534017A5 JP2020534017A5 (enExample) 2021-10-28
JP7303802B2 true JP7303802B2 (ja) 2023-07-05

Family

ID=65810903

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020516818A Active JP7303802B2 (ja) 2017-09-23 2018-09-21 Ａ３３抗体組成物および放射性免疫療法におけるその使用方法
JP2023103361A Pending JP2023138957A (ja) 2017-09-23 2023-06-23 Ａ３３抗体組成物および放射性免疫療法におけるその使用方法
JP2024215117A Pending JP2025061650A (ja) 2017-09-23 2024-12-10 Ａ３３抗体組成物および放射性免疫療法におけるその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023103361A Pending JP2023138957A (ja) 2017-09-23 2023-06-23 Ａ３３抗体組成物および放射性免疫療法におけるその使用方法
JP2024215117A Pending JP2025061650A (ja) 2017-09-23 2024-12-10 Ａ３３抗体組成物および放射性免疫療法におけるその使用方法

Country Status (9)

Country Link
US (2) US11555072B2 (enExample)
EP (1) EP3684369A4 (enExample)
JP (3) JP7303802B2 (enExample)
KR (1) KR102783937B1 (enExample)
CN (1) CN111372590A (enExample)
AU (2) AU2018338322B2 (enExample)
CA (1) CA3076611A1 (enExample)
IL (1) IL273484B2 (enExample)
WO (1) WO2019060750A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140271462A1 (en) 2013-03-13 2014-09-18 Imaginab, Inc. Antigen binding constructs to cd8
CN115960230A (zh) 2015-08-07 2023-04-14 伊麦吉纳博公司 靶向分子的抗原结合构建体
US11122038B1 (en) * 2017-05-18 2021-09-14 United Services Automobile Association (Usaa) Methods and systems for authentication of new users
EP3898677A1 (en) 2018-12-21 2021-10-27 OSE Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
SG11202106347PA (en) 2018-12-21 2021-07-29 Ose Immunotherapeutics Humanized anti-human-pd-1 antibody
EP3898676A1 (en) 2018-12-21 2021-10-27 OSE Immunotherapeutics Bifunctional anti-pd-1/sirpa molecule
CN113573782B (zh) 2018-12-21 2025-12-16 Ose免疫疗法公司 针对人pd-1的双功能分子
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
US20220177579A1 (en) * 2019-04-08 2022-06-09 Memorial Sloan Kettering Cancer Center Cd19 antibodies and methods of using the same
EP4244242A1 (en) 2020-11-16 2023-09-20 Technische Universität München Bioorthogonal reporter gene system
AU2021381768A1 (en) * 2020-11-18 2023-06-22 Memorial Sloan Kettering Cancer Center Anti-gpa33 multi-specific antibodies and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
WO2016130539A2 (en) 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
JP2017504578A (ja) 2013-08-23 2017-02-09 マクロジェニクス，インコーポレーテッド ｇｐＡ３３及びＣＤ３に結合二重特異性１価ダイアボディ、並びにその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307026B1 (en) * 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
DE69331735T2 (de) * 1992-12-10 2002-09-26 Celltech Therapeutics Ltd., Slough Gegen das A33 Antigen gerichtete Humanisierte Antikörper
JP2002512776A (ja) * 1998-04-28 2002-05-08 スミスクライン・ビーチャム・コーポレイション 免疫原性の低下したモノクローナル抗体
WO2006028197A1 (ja) * 2004-09-06 2006-03-16 Kirin Beer Kabushiki Kaisha 抗a33抗体
CN106794238A (zh) 2014-09-30 2017-05-31 威斯康星州医药大学股份有限公司 用于靶向治疗以治疗神经疾病的通用平台
DK3280432T3 (da) * 2015-04-06 2021-04-26 Subdomain Llc Polypeptider indeholdende de novo-bindingsdomæner og anvendelser deraf

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002512624A (ja) 1997-05-21 2002-04-23 バイオベーション リミテッド 非免疫原性タンパク質の製造方法
JP2017504578A (ja) 2013-08-23 2017-02-09 マクロジェニクス，インコーポレーテッド ｇｐＡ３３及びＣＤ３に結合二重特異性１価ダイアボディ、並びにその使用
WO2016130539A2 (en) 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
British Journal of Cancer，1995年，72，1364-1372
European Journal of Nuclear Medicine and Molecular Imaging，2016年05月，43, 5，925-937

Also Published As

Publication number Publication date
KR20200057759A (ko) 2020-05-26
JP2023138957A (ja) 2023-10-03
KR102783937B1 (ko) 2025-03-24
IL273484A (en) 2020-05-31
WO2019060750A3 (en) 2019-05-16
EP3684369A4 (en) 2021-06-23
AU2018338322A1 (en) 2020-04-09
WO2019060750A2 (en) 2019-03-28
AU2018338322B2 (en) 2025-07-17
US20200291112A1 (en) 2020-09-17
AU2025204844A1 (en) 2025-07-17
CA3076611A1 (en) 2019-03-28
IL273484B2 (en) 2025-12-01
US11555072B2 (en) 2023-01-17
EP3684369A2 (en) 2020-07-29
US20240327511A1 (en) 2024-10-03
CN111372590A (zh) 2020-07-03
JP2025061650A (ja) 2025-04-11
IL273484B1 (en) 2025-08-01
JP2020534017A (ja) 2020-11-26

Similar Documents

Publication Publication Date Title
JP7303802B2 (ja) Ａ３３抗体組成物および放射性免疫療法におけるその使用方法
US12486323B2 (en) Anti-L1-CAM antibodies and uses thereof
JP7791836B2 (ja) 抗ｃｄ３抗体及びその使用
US12441793B2 (en) CD33 antibodies and methods of using the same to treat cancer
JP7788859B2 (ja) がんを処置するための抗ｃｄ３３抗体
JP2022546572A (ja) 抗ｓｔｅａｐ１抗体およびその使用
US12195554B2 (en) Anti-polysialic acid antibodies and uses thereof
US20240026037A1 (en) Anti-gpa33 multi-specific antibodies and uses thereof
US20220242967A1 (en) Anti-glypican-3 antibodies and uses thereof
US20230374150A1 (en) Anti-psma antibodies and uses thereof
EA046795B1 (ru) Композиции на основе антител против a33 и способы их применения в радиоиммунотерапии

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210917

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230516

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230525

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230623

R150 Certificate of patent or registration of utility model

Ref document number: 7303802

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150